Clinical Trial

Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44

HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected…

2 months ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract…

2 months ago

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect…

2 months ago

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted…

2 months ago

Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on…

2 months ago

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and…

2 months ago

Rectify Pharma to Host Virtual R&D Event on RTY-694 for Primary Sclerosing Cholangitis and Other Hepatobiliary Diseases on November 21, 2024

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs),…

2 months ago

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society…

2 months ago

Perceptive eClinical Launches ClinPhone 5: A Ground-breaking new RTSM Platform Delivering a Leap in Clinical Development Technology

Platform developed in collaboration with CRScube, capitalizing on learnings from world-leading pharma and biotech companies NOTTINGHAM, England, Nov. 11, 2024 /PRNewswire/…

2 months ago

Avirmax Inc. to Present at the ARVO Frontiers in Ocular Gene Therapy Research Conference

HAYWARD, Calif., Nov. 11, 2024 /PRNewswire/ -- Avirmax's Chief Executive and Scientific Officer, Dr. Shengjiang Shawn Liu, Ph.D., will chair the…

2 months ago